1. Pink Sheet
  2. >>R&D

Life After I-SPY Graduation: Neratinib Likely To Be Tested With Roche’s Perjeta

 
• By Emily Hayes

I-SPY 2 investigators are buoyed by “strong signal” for neratinib in high-risk subgroup in adaptive design study. Investors, however, are underwhelmed by results.

SAN DIEGO – Puma Biotechnology Inc.says its oral tyrosine kinase inhibitor neratinib will be tested in combination with Roche’s biologic Perjeta in the registrational phase of the I-SPY breast cancer program, which should give neratinib evidence with a partner that is both an emerging standard of care and could have a synergistic effect.

Positive results for neratinib with current standard-of-care treatment, Herceptin and paclitaxel, in HER2-positive, hormone receptor-negative breast cancer in the Phase...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

More from R&D

UK Looks To Auto-Match NHS Patients With Clinical Trials To Boost Recruitment

 
• By Vibha Sharma

The UK government is making it easier for millions of people to participate in clinical trials and is boosting transparency around how studies are delivered across the National Health Service.

Global Guideline Signals ‘Paradigm Shift’ For Pregnant And Breastfeeding Women, Says EMA

 
• By Anabel Costa-Ferreira

The European Medicines Agency expects the International Council for Harmonization’s new guideline will help address the critical lack of data on the use of medicinal products in pregnant and breastfeeding populations.

Profit-Sharing AI Model Proposed To Boost Korean Drug R&D

 
• By Jung Won Shin

A differentiated profit-sharing model to accelerate the use of AI in drug development using clinical and patient data is being proposed in South Korea, but the idea faces multiple practical challenges